SRS and refractory depression
Started by Ray D. Ayshun
Functional SRS is definitely not for wimps - per the supplementary materials they treated 140 Gy in a single fraction!
I treat AVMs and TGN all the time with SRS, but that's because they are well-validated and covered by insurance. I'm very interested in other functional treatments and believe they have the potential to modestly expand our repertoire. However, we need more data and Medicare needs to cover it. I hope that day comes.
I treat AVMs and TGN all the time with SRS, but that's because they are well-validated and covered by insurance. I'm very interested in other functional treatments and believe they have the potential to modestly expand our repertoire. However, we need more data and Medicare needs to cover it. I hope that day comes.
Rad onc needs to be exploring low dose RT for Alzheimers
The data look good and some of the anecdotes are incredible
The number of people diagnosed with Alzheimers per year equal the number of new breast and prostate cancer cases combined
The data look good and some of the anecdotes are incredible
The number of people diagnosed with Alzheimers per year equal the number of new breast and prostate cancer cases combined
Advertisement - Members don't see this ad
Looks like the trial from Beaumont is currently suspended due to lack of funding.
clinicaltrials.gov
ClinicalTrials.gov
clinicaltrials.gov
I'm wary of a lot of this, BUT am SUPER supportive of trying on trial. Much respect to those who try, but wonder how many failures will make radiation look like a bad idea. I won't lie it is worrisome to low dose Alzheimer's patients, but that's why we try I suppose. Can you link data?
Sounds like there are a lot of new advances in this area (ketamine, psilocybin, tms)
Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer’s Disease? - IOS Press
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by extracellular amyloid-β (Aβ ) peptide aggregates, forming amyloid plaques, and intracellular deposits of phosphorylated tau. Neuroinflammation is now considered as the third ha
Treatment of Alzheimer Disease With CT Scans: A Case Report - PMC
Alzheimer disease (AD) primarily affects older adults. This neurodegenerative disorder is the most common cause of dementia and is a leading source of their morbidity and mortality. Patient care costs in the United States are about 200 billion ...
www.ncbi.nlm.nih.gov
The prognosis for AD is so dismal, and the # of treatments so lacking, I’m surprised there isn’t more support to complete a trial.Looks like the trial from Beaumont is currently suspended due to lack of funding.
ClinicalTrials.gov
Maybe the Germans will get it done.
Perhaps Emory can do a low dose WBRT for anti-vaxxers in order to finally show a benefit for RT in Covid.
Advertisement - Members don't see this ad
WBRT + WLI = half body irradiation!
Alzheimers is really a huge unmet need, several times larger than cancer, "The Next Pandemic," as one recent article called it.
Good animal data and case reports but no US center has yet to successfully accrue. Would need a solid network effort.
Good animal data and case reports but no US center has yet to successfully accrue. Would need a solid network effort.
Xrt would be cheaper than the non therapy the FDA approved recently
And if XRT were a drug and given its preclinical promise, pharma would have a billion dollar investment (minimum) in it right now.
(Still expect some leading rad oncs to write an editorial about second cancer risks in 80 year olds getting Alzheimer’s RT.)
Last edited:
D
deleted941485
Trust me some junior RO faculty is writing that editorial for the RJ as we speak thinking that the tenure committee will count it as a pub! Maybe they’ll even sweeten the pot and put some other faculty members on it for little more than glancing at the pdf they’ll attach to some desperate email at 1am in the morning. Mom and dad must be so proud.
Last edited by a moderator:
FYI: semaglutide approved for treatment of both niddm and obesity has entered phase 3 in Alzheimer’s. A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) - Full Text View - ClinicalTrials.gov
